Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.
Hishiki T, Morita T, Akazawa D, Ohashi H, Park ES, Kataoka M, Mifune J, Shionoya K, Tsuchimoto K, Ojima S, Azam AH, Nakajima S, Kawahara M, Yoshikawa T, Shimojima M, Kiga K, Maeda K, Suzuki T, Ebihara H, Takahashi Y, Watashi K. Hishiki T, et al. Among authors: takahashi y. Microbiol Spectr. 2023 Aug 17;11(4):e0056623. doi: 10.1128/spectrum.00566-23. Epub 2023 Jul 6. Microbiol Spectr. 2023. PMID: 37409948 Free PMC article.
Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1.
Yato K, Onodera T, Matsuda M, Moriyama S, Fujimoto A, Watashi K, Aizaki H, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Tamura K, Takahashi Y, Wakita T, Muramatsu M, Kato T, Suzuki R. Yato K, et al. Among authors: takahashi y. J Virol. 2021 Mar 1;95(5):e01680-20. doi: 10.1128/JVI.01680-20. Epub 2020 Dec 9. J Virol. 2021. PMID: 33298539 Free PMC article.
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.
Shionoya K, Yamasaki M, Iwanami S, Ito Y, Fukushi S, Ohashi H, Saso W, Tanaka T, Aoki S, Kuramochi K, Iwami S, Takahashi Y, Suzuki T, Muramatsu M, Takeda M, Wakita T, Watashi K. Shionoya K, et al. Among authors: takahashi y. Front Microbiol. 2021 Apr 30;12:651403. doi: 10.3389/fmicb.2021.651403. eCollection 2021. Front Microbiol. 2021. PMID: 33995308 Free PMC article.
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Moriyama S, et al. Among authors: takahashi y. Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2. Immunity. 2021. PMID: 34246326 Free PMC article.
Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H, Yamamoto Y, Koseki T, Banno S, Ando T, Ito H, Fujita T, Naruse H, Hata T, Moriyama S, Takahashi Y, Suzuki T, Murakami T, Yoshida Y, Yagura Y, Oyamada T, Takemura M, Kondo M, Iwata M, Saito K. Fujigaki H, et al. Among authors: takahashi y. Microbiol Spectr. 2022 Feb 23;10(1):e0118121. doi: 10.1128/spectrum.01181-21. Epub 2022 Jan 19. Microbiol Spectr. 2022. PMID: 35044205 Free PMC article.
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses.
Ishii H, Nomura T, Yamamoto H, Nishizawa M, Thu Hau TT, Harada S, Seki S, Nakamura-Hoshi M, Okazaki M, Daigen S, Kawana-Tachikawa A, Nagata N, Iwata-Yoshikawa N, Shiwa N, Suzuki T, Park ES, Ken M, Onodera T, Takahashi Y, Kusano K, Shimazaki R, Suzaki Y, Ami Y, Matano T. Ishii H, et al. Among authors: takahashi y. Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233545 Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: takahashi y. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2.
Saso W, Yamasaki M, Nakakita SI, Fukushi S, Tsuchimoto K, Watanabe N, Sriwilaijaroen N, Kanie O, Muramatsu M, Takahashi Y, Matano T, Takeda M, Suzuki Y, Watashi K. Saso W, et al. Among authors: takahashi y. PLoS Pathog. 2022 Jun 14;18(6):e1010590. doi: 10.1371/journal.ppat.1010590. eCollection 2022 Jun. PLoS Pathog. 2022. PMID: 35700214 Free PMC article.
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K, Tsuchimoto K, Iwanami S, Moriyama S, Kinoshita H, Yamada S, Kuroda Y, Yamamoto T, Kishida N, Watanabe S, Hasegawa H, Ebihara H, Suzuki T, Maeda K, Fukushi S, Takahashi Y, Iwami S, Watashi K. Ohashi H, et al. Among authors: takahashi y. Antiviral Res. 2022 Sep;205:105372. doi: 10.1016/j.antiviral.2022.105372. Epub 2022 Jul 4. Antiviral Res. 2022. PMID: 35798223 Free PMC article.
12,147 results
You have reached the last available page of results. Please see the User Guide for more information.